Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive following a flurry of announcements from the biotech company.
Reginald gives an overview of three recent developments, including the results of trials into treatments for osteosarcoma and Midkine-expressing cancers.
He also highlights recent increases in the level of investment in the company by himself and by executive chairman Stephen West.